SAN DIEGO, California, August 11, 2026
Belite Bio, Inc. announced that the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review to the company’s New Drug Application (NDA) for tinlarebant for the treatment of Stargardt Disease Type 1 (STGD1). The FDA has established a Prescription Drug User Fee Act (PDUFA) target action date of February 12, 2027. The regulatory milestone brings tinlarebant closer to a potential approval for a rare inherited retinal disorder for which there is currently no approved treatment. If approved, tinlarebant could become the first FDA-approved treatment for Stargardt Disease Type 1, according to Belite Bio.
FDA Priority Review Follows Phase 3 DRAGON Results
The NDA is supported by results from the pivotal Phase 3 DRAGON trial, which evaluated tinlarebant in patients with STGD1. According to Belite Bio, the study demonstrated a statistically significant and clinically meaningful 35.7% reduction in the growth rate of atrophic retinal lesions compared with placebo. The lesion growth was measured using definitely decreased autofluorescence (DDAF) through fundus autofluorescence imaging. The findings provided the clinical foundation for the regulatory submission and represent an important development milestone for tinlarebant. Belite Bio reported that tinlarebant has generally been well tolerated in clinical studies, with adverse effects described as consistent with its mechanism of action. The FDA’s Priority Review designation means the application will receive an expedited review process compared with a standard review. The agency’s target action date of February 12, 2027 provides the current regulatory timeline for a decision on the NDA, although approval is not guaranteed.
Tinlarebant Targets Stargardt Disease Mechanism
Stargardt Disease Type 1 is a rare inherited retinal disease caused by mutations in the ABCA4 gene and is associated with progressive and irreversible vision loss. The condition often develops early in life and can significantly affect visual function as retinal damage progresses. Belite Bio estimates that approximately 53,000 people in the United States are affected by STGD1. The company is developing tinlarebant as an oral therapy designed to address a biological pathway involved in the accumulation of toxic compounds within the retina. Tinlarebant, also known as LBS-008, is designed to reduce the accumulation of vitamin A-derived bisretinoids in the eye. These compounds are by-products of the visual cycle and are believed to contribute to retinal disease progression. Tinlarebant works by reducing and maintaining levels of retinol-binding protein 4 (RBP4), the primary carrier protein responsible for transporting retinol from the liver to the eye. By modulating retinol delivery to the retina, the therapy is intended to reduce the formation of bisretinoids and potentially slow disease progression.
Advertisement
Belite Bio Advances Retinal Disease Pipeline
The FDA has granted tinlarebant several regulatory designations for Stargardt disease, including Breakthrough Therapy, Fast Track, Rare Pediatric Disease, and Orphan Drug designations in the United States, while Orphan Drug Designation has also been granted in Europe, Japan, and Switzerland. Tinlarebant has additionally received Sakigake Designation in Japan, highlighting the regulatory attention surrounding the investigational therapy. Belite Bio has completed the Phase 3 DRAGON trial, while continuing to evaluate tinlarebant in the Phase 2/3 DRAGON II trial in adolescent and adult patients with STGD1. The company is also studying the therapy in the Phase 3 PHOENIX trial for patients with geographic atrophy associated with advanced dry age-related macular degeneration. These programs form the core of Belite Bio’s strategy to develop therapies for degenerative retinal diseases with significant unmet medical needs. The FDA acceptance and Priority Review of the tinlarebant NDA represent a major regulatory milestone for Belite Bio and the Stargardt disease community. If the FDA approves the application, tinlarebant could introduce the first approved pharmacological treatment for STGD1, potentially providing a new therapeutic option for patients facing progressive vision loss. Until the FDA completes its review, the drug remains investigational and its ultimate safety, efficacy, and approval status will depend on regulatory evaluation.
Source: Belite Bio press release
